CD44 and melanoma: Of note, combination of the FITC-pretargeting scFvFITC:sTRAIL strategy with proteasome inhibitor bortezomib significantly enhanced apoptosis in 2 out of 3 primary OC samples when pretargeted with anti-CD44-FITC (Fig. 2F), whereas cotreatment with vemurafenib enhanced scFvFITC:sTRAIL-induced apoptosis in 4 out of 4 patient-derived primary melanoma cell cultures (Fig. 2H).